Psoriatic Arthritis - KOL Insight

Insights from leading KOLs on the evolving landscape of psoriatic arthritis (PsA) treatment. From the continued dominance of anti-TNFs due to their proven safety and efficacy to Bimzelx's potential as a niche treatment and Skyrizi/Tremfya's superior efficacy in managing skin symptoms, this report examines current and emerging therapies providing valuable insights into the strategic preferences and practices that are shaping clinical decisions in PsA management today.

Table of Contents

Executive summary

Current and future treatment algorithm for psoriatic arthritis

Research objectives

Approved drugs (105)

• Anti-tumour necrosis factor agents
  • Key insights summary
• Interleukin-17 inhibitors
  • Cosentyx (secukinumab; Novartis)
  • Taltz (ixekizumab; Lilly)
  • Bimzelx (bimekizumab; UCB)
• Interleukin-12/23 and interleukin-23 inhibitors
  • Stelara (ustekinumab; Johnson & Johnson)
  • Skyrizi (risankizumab; AbbVie/Boehringer Ingelheim)
  • Tremfya (guselkumab; Johnson & Johnson)
• Janus kinase (JAK) inhibitors
  • Xeljanz (tofacitinib; Pfizer)
  • Rinvoq (upadacitinib; AbbVie)
• T-cell activation inhibitors
  • Orencia (abatacept; Bristol Myers Squibb)
• Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Otezla (apremilast; Amgen)

Pipeline drugs

• Interleukin-17 inhibitors
  • Brodalumab (AstraZeneca/LEO Pharma)
  • Izokibep (Affibody/ACELYRIN) and sonelokimab (MoonLake Immunotherapeutics)
• Interleukin-23 inhibitors
  • Ilumya/Ilumetri (tildrakizumab; Almirall/Sun Pharmaceutical)
• Tyrosine kinase 2 (TYK2) inhibitors
  • Sotyktu (deucravacitinib; Bristol Myers Squibb)
  • TAK-279 (Takeda)
• Kv1.3 potassium channel inhibitor
  • si-544 (selectION)

Future trends and opportunities in psoriatic arthritis treatment

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe

KOL Bulletins